Last Update 22 Mar 26
Fair value Decreased 1.71%MIR: 2026 Guidance And Margin Assumptions Will Support Constructive Long Term Upside
Analysts have trimmed their price target for Mirion Technologies by $0.50 to $28.80, reflecting a slightly higher discount and modestly adjusted fair value and future P/E assumptions, while keeping revenue growth and profit margin expectations broadly unchanged.
What's in the News
- Mirion Technologies reported that between October 1, 2025 and December 31, 2025, it repurchased 0 shares for $0 million under its existing buyback program. (Key Developments)
- The company has completed the previously announced buyback program, repurchasing a total of 1,160,000 shares for $18.56 million, equal to 0.56% of its shares. (Key Developments)
- Mirion issued earnings guidance for the fiscal year ending December 31, 2026, indicating expected revenue growth of about 22% to 24%, which includes effects from foreign exchange and acquisitions. (Key Developments)
Valuation Changes
- Fair Value: trimmed from $29.30 to $28.80, a small downward adjustment to the estimated equity value.
- Discount Rate: nudged higher from 8.92% to 9.01%, implying a slightly higher required return for Mirion's cash flows.
- Revenue Growth: kept effectively unchanged at about 12.46%, indicating no material revision to top line expectations in the model.
- Net Profit Margin: held steady at about 10.48%, with no meaningful change to assumed profitability.
- Future P/E: eased from 82.03x to 80.83x, reflecting a modestly lower multiple applied to forward earnings in the updated assumptions.
Key Takeaways
- Expansion in nuclear power and new digital solutions are driving stable, high-margin growth and broadening recurring revenue streams.
- Financial flexibility from capital structure optimization supports further acquisitions, technology investments, and enhanced cash generation.
- Heavy reliance on nuclear sector and acquisitions exposes Mirion to market, integration, and regulatory risks, challenging its revenue growth and long-term earnings stability.
Catalysts
About Mirion Technologies- Provides radiation detection, measurement, analysis, and monitoring products and services in North America, Europe, and the Asia Pacific.
- The accelerating global shift toward expanded nuclear power generation, coupled with rising capital budgets for modernization, life extensions, and increased capacity of the existing reactor fleet, is likely to drive sustained double-digit organic revenue growth and expand Mirion's higher-margin installed base business in coming years.
- Strong momentum in advanced nuclear projects-including utility-scale new builds and rapid activity in the small modular reactor (SMR) market-has materially broadened Mirion's pipeline of large, multi-year opportunities, creating potential for significant step-changes in future order intake, backlog, and top-line revenue.
- Heightened focus on regulatory compliance, radiation safety, and operational efficiency-both in the nuclear and wider healthcare sectors-is resulting in recurring demand for Mirion's specialized detection, monitoring, and dosimetry solutions, supporting stable, visible revenue streams and improved customer retention.
- Continued rollout of new digital platforms, such as the Vital and Apex-Guard software, along with the strategic Certrec acquisition (bringing SaaS-based, AI-enabled compliance tools), positions Mirion to capture premium pricing, drive software mix expansion, and unlock operating leverage, benefitting margins and long-term earnings potential.
- Recent investment in capital structure optimization has reduced interest expense and increased financial flexibility, enabling additional M&A and technology investments while freeing up cash flow that may be deployed to accretive growth initiatives or returned to shareholders, improving net margin and cash generation over time.
Mirion Technologies Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Mirion Technologies's revenue will grow by 12.5% annually over the next 3 years.
- Analysts assume that profit margins will increase from 3.1% today to 10.5% in 3 years time.
- Analysts expect earnings to reach $138.0 million (and earnings per share of $0.44) by about March 2029, up from $28.8 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 81.0x on those 2029 earnings, down from 156.7x today. This future PE is greater than the current PE for the US Electronic industry at 28.5x.
- Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 9.01%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Revenue concentration in the nuclear sector exposes Mirion to long-term risks from a shrinking pipeline of new nuclear builds, especially in Western markets, where regulatory, political, and financial challenges may limit future addressable market expansion, potentially capping long-term revenue growth.
- The emphasis on modernization and life extension of existing nuclear reactors is positive now, but reliance on aging fleets means that decommissioning, policy shifts, or anti-nuclear sentiment could reverse these trends, introducing structural volatility and long-term demand uncertainty for Mirion's core products, risking future revenue and earnings.
- Mirion's acquisition-led growth strategy, including the recent Certrec purchase, increases execution and integration risks-failure to realize expected synergies or elevated SG&A expenses may compress net margins and dilute earnings quality over the long term.
- Expanding investment in new digital and AI-driven solutions is necessary to maintain competitiveness, but escalating competition from low-cost international suppliers and technology commoditization could erode Mirion's pricing power, compressing margins and impacting long-term profitability.
- The medical and Labs & Research segments are vulnerable to government budgetary pressures (e.g., DOGE, Medicaid cuts), while broader healthcare shifts toward alternative, radiation-free imaging technologies could reduce long-term demand for Mirion's products, weighing on diversified revenue and future earnings stability.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $28.8 for Mirion Technologies based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.3 billion, earnings will come to $138.0 million, and it would be trading on a PE ratio of 81.0x, assuming you use a discount rate of 9.0%.
- Given the current share price of $18.45, the analyst price target of $28.8 is 35.9% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Mirion Technologies?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

